Press release
Bristol inks two combo deals after Opdivo miss - news addition by iData Insights
www.omensol.wordpress.com
Brief:
Bristol-Myers Squibb is testing its blockbuster immunotherapy Opdivo in two combinations with other oncology developers in an effort to further its combination strategy.
The big pharma has inked an early-stage collaboration with Aveo Oncology to test the biotech's once-daily, vascular endothelial growth factor tyrosine kinase inhibitor tivozanib with Opdivo, a PD-1 inhibitor.
Bristol-Myers will also supply Bavarian Nordic with a supply of Opdivo to test the drug in combination with the experimental CV301 in patients with non-small cell lung cancer (NSCLC).
Insight:
Despite a clinical setback last week for Opdivo (nivolumab) in the first-line setting of NSCLC, Bristol-Myers is undeterred in its pursuit of a strong clinical profile for the checkpoint inhibitor.
The big pharma has previously said it will focus on combination therapies including Opdivo to further differentiate the drug. Since its FDA approval last summer, Opdivo has quickly outpaced Merck's rival PD-1 inhibitor Keytruda (pembrolizumab), racking up sales and new indications. The failure in first-line NSCLC opens...
Read More: http://www.omensol.wordpress.com/hcp-updates/bristol/
For more info Contact:
Susana Simon
PA to MD
mark@idatainsights.com
1866-237-2965
+91 875 003 0003
Portland, OR
United States
iData Insights which operates under Precision Research and Consulting Pvt. Ltd. is a marketing research consulting firm. Its efforts help companies to create and improve products and services based on what the market desires. We conduct both primary and secondary research. Our work does not end with research. We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.
iData Insights
NE Airport Way, 355991,
Portland, Oregon, 97230
United States
Susana Simon
PA to MD
mark@idatainsights.com
1866-237-2965
+91 875 003 0003
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bristol inks two combo deals after Opdivo miss - news addition by iData Insights here
News-ID: 356785 • Views: …
More Releases from iData Insights
PrivatePlus Mortgage Grows Management Team with Addition of Christine Conley Jr. …
PrivatePlus Mortgage, a division of National Bank of Commerce, has named mortgage veteran Christine Conley Jr. as Senior Vice President, Operations. She oversees the overall Operations, ensuring loans are originated and processed according to PPM’s guidelines.
“Christine has been in the mortgage industry for 30 years, serving in a broad range of positions, which gives her great perspective on each player’s role and what it ultimately means to our clients,” says…
Insulin Market is Growing at 10.29% to 2019 - iData Insights
Insulin Market is Growing at 10.29% to 2019 - iData Insights
According to the most up-to-data market data on the actual market situation and future outlook for insulin in the World, mainly in China, Denmark, France, Germany, India, Indonesia, Italy, Japan, Russia, and United States has shown the market is growing at 10.29% to 2019 and it is confirmed by iData Insights recently.
Insulin Market is Growing at 10.29% to 2019 is…
Insulin Market to 2019 - Market Size, Development, Top 10 Countries, and Forecas …
Insulin Market to 2019 - Market Size, Development, Top 10 Countries, and Forecasts
The industry study package Insulin Market to 2019 - Market Size, Development, Top 10 Countries, and Forecasts offers the most up-to-date market data on the actual market situation, and future outlook for insulin in the world and in the top 10 global countries. Along with a global insulin market study the package includes country reports from the following…
Oil & Gas Industry Google+ OMEN News Page Launch by Mark Stainer, iData Insights …
To Visit Google+ Oil & Gas Industry OMEN News Page, go to: plus.google.com/u/0/collection/kPRxbB
iData Insights is pleased to announce that as part of its continuing social media outreach efforts, it has launched a Google+ Oil & Gas Industry OMEN News Page. The page will be used as hub of helpful News, Articles, Information for Oil & Gas Industry, providing Oil & Gas Industry Professionals with links to useful information that will…
More Releases for Opdivo
Impact of Rising Non-Small Cell Lung Cancer Incidence on Opdivo (Nivolumab) Mark …
What market dynamics are playing a key role in accelerating the growth of the opdivo (nivolumab) market?
Anticipated advancements in the opdivo (nivolumab) market are primarily driven by the rising prevalence of non-small cell lung cancer. This type accounts for approximately 85% of all lung cancer diagnoses. Factors such as smoking, exposure to environmental contaminants, genetic mutations, and a familial history of cancer contribute to the growing incidence of non-small cell…
Major Market Shift in Yervoy Industry: Innovative Combination Therapies Yervoy A …
What Is the Estimated Market Size and Growth Rate for the Yervoy Market?
Recent years have seen a swift escalation in the Yervoy market size. It is projected to surge from $5,420 million in 2024 to $6,010 million in 2025, exhibiting a compound annual growth rate (CAGR) of 10.9%. The substantial growth during the historic period is a result of a rise in cancer incidence, a heightened focus on combination treatments,…
Comprehensive Opdivo (nivolumab) Market Insights: Forecasting Size, Growth, and …
"What Is the Future Outlook for the Opdivo (nivolumab) Market's Size and Growth Rate?
The market size of opdivo (nivolumab) has seen substantial growth in the past few years. It's projected to rise from $7,709.49 million in 2024 to $8,335.54 million in 2025, with a compound annual growth rate (CAGR) of 8.1%. This past growth is due to factors such as higher rates of cancer, increased spending on research and development…
The Market share for Opdivo (nivolumab) + Yervoy (ipilimumab) by Bristol Myers S …
[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on Opdivo (nivolumab) + Yervoy (ipilimumab) (Bristol Myers Squibb) providing insights into the drug market landscape and market forecast of Opdivo (nivolumab) + Yervoy (ipilimumab) upto 2032. The report, titled "Opdivo (nivolumab) + Yervoy (ipilimumab) Market Size, Forecast, and Drug Insight - 2032" is now available for review and analysis.
Are you interested…
Opdivo Drug Market (Opdivo in the Treatment of Metastatic Colorectal Cancer): Ex …
(New York, USA) The Opdivo (nivolumab) + Yervoy (ipilimumab) market forecast report provides analysis of Opdivo (nivolumab) + Yervoy (ipilimumab) market analysis and forecasts upto 2032 in the major markets. The comprehensive report provides analysis of Opdivo (nivolumab) + Yervoy (ipilimumab) market potential and Opdivo (nivolumab) + Yervoy (ipilimumab) market share analysis in Metastatic Colorectal Cancer across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and…
Opdivo Drug Market Forecast and Analysis (Opdivo for Metastatic Colorectal Cance …
(New York, USA) The Opdivo (nivolumab) + Yervoy (ipilimumab) market forecast report provides analysis of Opdivo (nivolumab) + Yervoy (ipilimumab) market analysis and forecasts upto 2032 in the major markets. The comprehensive report provides analysis of Opdivo (nivolumab) + Yervoy (ipilimumab) market potential and Opdivo (nivolumab) + Yervoy (ipilimumab) market share analysis in Metastatic Colorectal Cancer across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and…
